Cytokinetics to present new data on aficamten for hypertrophic cardiomyopathy at AHA 2026 sessions

Cytokinetics announced three presentations at the 2026 Hypertrophic Cardiomyopathy Medical Society Scientific Sessions in collaboration with the American Heart Association. The presentations will showcase new data on aficamten, including its effects on cardiac structure and patient health in nonobstructive hypertrophic cardiomyopathy, and long-term therapy outcomes for obstructive HCM. Positive Phase 3 trial results support a planned supplemental drug application in late 2026. This highlights Cytokinetics' ongoing development of treatments for cardiac muscle diseases.

Cytokinetics Inc (CYTK) shares are stable at USD 62.99 on Pluang as of Nov 02, 2026 19:21 WIB. The stock shows no change today with a market cap of $8.77 billion. Trading volume is 1,257,213, reflecting steady investor interest amid ongoing developments in cardiac treatments.